Fermenta Biotech Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹137Cr
- −12.2% YoY
- +5.5% QoQ
- Net profit
- ₹12Cr
- −68.3% YoY
- −33.3% QoQ
- Margin
- 18.17%
- −15.9 pp YoY
- −2.3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Fermenta Biotech Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ) - 9moFY26 Revenue: INR 421.2 crore (up 25% YoY) - Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ) - 9moFY26 EBITDA: INR 97.2 Q3FY26 EBITDA: INR 28.1 crore, down 49% YoY - Q3FY26 Profit after Tax (PAT): INR 12.0 crore, down 68% YoY - Q3FY26 Revenue: INR 140.5 crore, down 11% YoY (for context)
From Fermenta Biotech Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ)
- 9moFY26 Revenue: INR 421.2 crore (up 25% YoY)
- Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ)
- 9moFY26 EBITDA: INR 97.2 crore (up 20% YoY)
- Q3FY26 Profit after tax: INR 12.0 crore (down 68% YoY, down 33% QoQ)
- 9moFY26 Profit after tax: INR 51.7 crore (up 20% YoY)
- Human nutrition segment volumes grew 46% over 9MFY25
- Animal nutrition segment volumes grew 52% over 9MFY25, despite an 8% decline in average realization
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 137 | 156 | -12.2% | 130 | +5.5% |
| Operating profit (EBITDA) | 25 | 53 | -53.1% | 27 | -6.3% |
| Operating margin | 18.17% | 34.04% | -15.9 pp | 20.46% | -2.3 pp |
| Profit before tax | 17 | 45 | -61.4% | 24 | -27.4% |
| Net profit (PAT) | 12 | 38 | -68.3% | 18 | -33.3% |
| EPS (₹) | 4.31 | 12.54 | -65.6% | 6.14 | -29.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q3 FY26 results?
Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ) - 9moFY26 Revenue: INR 421.2 crore (up 25% YoY) - Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ) - 9moFY26 EBITDA: INR 97.2 Q3FY26 EBITDA: INR 28.1 crore, down 49% YoY - Q3FY26 Profit after Tax (PAT): INR 12.0 crore, down 68% YoY - Q3FY26 Revenue: INR 140.5 crore, down 11% YoY (for context)
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
